TC BioPharm (TCBP) announced a partnership with CareDx (CDNA) who will perform pharmacokinetic analysis using its AlloCellsolution in the ACHIEVE clinical trial. The ACHIEVE clinical trial is an adaptive, open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma delta T cell therapy for patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome. CareDx is a leading precision medicine company focused on discovering, developing, and commercializing healthcare solutions for transplant patients and caregivers. CareDx’s AlloCell test, a sensitive solution for pharmacokinetic monitoring of allogeneic immune and stem cell therapies, will be used to evaluate the expansion and persistence of TCB008 in patients enrolled in the ACHIEVE trial.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TCBP:
- TC Biopharm price target lowered to $3 from $7 at H.C. Wainwright
- TC Biopharm provides quarterly update on ACHIEVE UK Trial
- TC Biopharm files $100M mixed securities shelf
- TC Biopharm Faces Financial Strains Amid Rising Costs
- TC Biopharm awarded funding of $250,000 from G-Rex Grant Program
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
